Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PF3F | ISIN: US70465T1079 | Ticker-Symbol: EU6
Tradegate
27.06.25 | 11:26
1,224 Euro
+1,92 % +0,023
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PDS BIOTECHNOLOGY CORPORATION Chart 1 Jahr
5-Tage-Chart
PDS BIOTECHNOLOGY CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
1,1801,22013:03
1,1821,21827.06.

Aktuelle News zur PDS BIOTECHNOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiPDS Biotechnology Corp - 8-K, Current Report3
11.06.PDS Biotechnology Corp - 8-K, Current Report4
PDS BIOTECHNOLOGY Aktie jetzt für 0€ handeln
11.06.H.C. Wainwright maintains Buy rating on PDS BIOTECHNOLOGY stock13
09.06.PDS Biotechnology Corporation: PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune HPV for the Treatment of HPV16+ HNSCC3
02.06.PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial3
02.06.PDS Biotechnology Corp - 8-K, Current Report1
02.06.PDS Biotechnology Corporation: PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology ...130Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial abstract HPV16-positive is...
► Artikel lesen
27.05.PDS Biotechnology files to sell 9.82M shares of common stock for holders5
23.05.PDS Biotechnology Corporation (PDSB)'s Versamune HPV Surpasses Survival Benchmarks in Recurrent Head and Neck Cancer Trial4
22.05.PDS Biotech reports extended survival in HPV cancer study7
22.05.PDS Biotechnology Corporation: PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) ...110Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS =20 is 39.3 months - Median overall survival for CPS =1 is 30.0 months...
► Artikel lesen
22.05.PDS Biotechnology Corp - 8-K, Current Report1
20.05.PDS Biotechnology Corporation: PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase4
14.05.PDS Biotechnology Corp - 10-Q, Quarterly Report2
14.05.PDS Biotech treibt Phase-3-Studie voran und veröffentlicht Finanzergebnisse für Q16
14.05.PDS Biotech advances Phase 3 trial, reports Q1 financials1
14.05.PDS Biotechnology GAAP EPS of -$0.21 beats by $0.041
14.05.PDS Biotechnology Corporation: PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update168VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00...
► Artikel lesen
14.05.PDS Biotechnology Corp - 8-K, Current Report1
13.05.Insights Ahead: PDS Biotechnology's Quarterly Earnings1
Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1